title: A prospective comparison of in vitro fertilization (IVF) outcome following controlled ovarian hyperstimulation (COH) regimens using follitropin alpha exclusively or with the addition of low dose human chorionic gonadotropin (hCG) and ganirelix.
abstract: OBJECTIVE
  To determine if the addition of luteinizing hormone (LH) activity to a controlled ovarian hyperstimulation regimen for purposes of in vitro fertilization adds any additional benefit to the exclusive use of recombinant (r) FSH in antagonist protocols.
  
  
  METHODS
  Women with normal endogenous gonadotropin levels were randomly assigned to receive either follitropin alpha exclusively or have the addition of 25 IU human chorionic gonadotropin (hCG) daily. Ganirelix was used when a 14 mm follicle was attained. The data would be analyzed after 70 women were selected for the study and divided into two groups.
  
  
  RESULTS
  There were 22 women in each group who proceeded with embryo transfer (some purposely cryopreserved all embryos because of risk of ovarian hyperstimulation syndrome). There were no trends for differences in clinical or delivered pregnancy rates or implantation rates.
  
  
  CONCLUSIONS
  There does not appear to be any clinical advantage of adding exogenous LH activity to the drug regimen for stimulation of multiple follicles for purposes of in vitro fertilization when using follitropin alpha in an antagonist protocol.
authors.affiliation: The University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ, USA. laurie@ccivf.com
authors.forename: J H
authors.initials: JH
authors.lastname: Check
authors.forename: E
authors.initials: E
authors.lastname: Davies
authors.forename: D
authors.initials: D
authors.lastname: Brasile
authors.forename: J K
authors.initials: JK
authors.lastname: Choe
authors.forename: J
authors.initials: J
authors.lastname: Amui
mesh_terms: D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D010064:Embryo Implantation; D005260:Female; D005307:Fertilization in Vitro; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage*; D015292:Glycoprotein Hormones, alpha Subunit / Q000008:administration & dosage*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D007986:Luteinizing Hormone / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate
chemical_list: D006063:Chorionic Gonadotropin; D043373:Follicle Stimulating Hormone, Human; D015292:Glycoprotein Hormones, alpha Subunit; D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; C061018:ganirelix